JournalBMJ Evidence-based Medicine
PublisherBMJ Publishing Group
MetadataShow full item record
AbstractGlobally, drug regulators have approved statins for the prevention of cardiovascular disease (CVD), although their use in primary prevention has been controversial. A highly publicised debate has ensued over whether the benefits outweigh the harms. Drug regulators, which are legally required to make independent judgements on drug approvals, have remained silent during the debate. Our aim was to navigate the decision-making processes of European drug regulators and ultimately request the data upon which statins were approved. Our findings revealed a system of fragmented regulation in which many countries licensed statins but did not analyse the data themselves. There is no easily accessible archive containing information about the licensing approval of statins or a central location for holding the trial data. This is an unsustainable model and serves neither the general public, nor researchers.
Keywordcoronary heart disease
ischaemic heart disease
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Clinical Trials as Topic
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/12223
- A systematic review and economic evaluation of statins for the prevention of coronary events.
- Authors: Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N
- Issue date: 2007 Apr
- Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks.
- Authors: Minder CM, Blumenthal RS, Blaha MJ
- Issue date: 2013 Sep
- Fixed-dose combination therapy with statins: strengths, limitations, and clinical and regulatory considerations.
- Authors: Hennekens CH
- Issue date: 2008
- Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of 'deep' product reviews.
- Authors: Mulinari S, Davis C
- Issue date: 2017 Nov 9